Threshold Pharmaceuticals Announces Multiple Data Presentations on TH-302 at the 2012 AACR Annual Meeting
Oral, Late-Breaking Presentation and Subsequent Webcast to Detail Efficacy and Safety Data From Phase 2b Trial of TH-302 in Pancreatic Cancer
(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/28/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that TH-302 will be featured in four presentations, including a late-breaking clinical trial session, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on March 31 - April 4, 2012, in Chicago, IL. Together, the presentations will detail the results of studies combining TH-302, a hypoxia-targeted drug, with currently available therapies such as gemcitabine, Chk1 inhibitors and mTOR inhibitors in the treatment of various solid tumors and hematologic malignancies. The late-breaking oral presentation will report efficacy and safety data from the randomized Phase 2b trial of TH-302 plus gemcitabine versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. Threshold announced last month that the trial achieved its primary endpoint, with a 63% improvement in progression free survival and a safety profile consistent with previous studies, but the detailed findings have been reserved for the AACR meeting.
A conference call and audio webcast will be held Monday, April 2, 2012 at 1:30 PM CT following the late-breaking oral presentation. Conference call dial in and webcast log in details are as follows:
North American callers dial:
1 (866) 516-3867
International callers dial:
1 (253) 237-1160
Participant Conference ID: 66606492
To access the call online via webcast, please click , or visit .
The title, schedule and location are provided below for each of Threshold's presentations. Per AACR policy, all data are embargoed until the presentation begins.
Session Date/Time: Monday, April 2, 2012 10:30AM - 12:30PM CT
Location: McCormick Place West (Level 1), Room W192
Presenter: Dr. Mitesh J. Borad, Principal Investigator
Session Date/Time: Monday, April 2, 2012 8:00AM - 12:00PM CT
Location: McCormick Place West (Hall F), Poster Section 28
Lead Author: Dr. Fanying Meng
Session Date/Time: Tuesday, April 3, 2012 8:00AM - 12:00PM CT
Location: McCormick Place West (Hall F), Poster Section 28
Lead Author: Dr. Jessica D. Sun
Session Date/Time: Tuesday, April 3, 2012 1:00PM - 5:00PM CT
Location: McCormick Place West (Hall F), Poster Section 28
Lead Author: Dr. Juliana M. Benito
Copies of the presentation and posters will be available at following the close of the sessions.
TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark of many cancer indications. Areas of low oxygen levels (hypoxia) within tissues are common in many solid tumors due to insufficient blood vessel growth. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be extremely hypoxic.
TH-302 has been investigated in over 600 patients in Phase 1/2 clinical trials to date in a broad spectrum of tumor types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs. Threshold has several additional ongoing clinical trials, the most advanced of which is a Phase 3 pivotal study evaluating TH-302 in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma, and recently completed a Phase 2b trial of TH-302 in combination with gemcitabine versus gemcitabine alone in pancreatic cancer. In February 2012, Threshold signed a global agreement with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302.
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ().
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302's potential ability to treat cancers, planned clinical trials and anticipated results, and potential therapeutic uses and benefits of TH-302. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, whether such trials confirm results from earlier trials and preclinical studies, potential side effects associated with TH-302, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results), and Threshold's ability to raise additional capital to continue funding its operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission on March 15, 2012 and is available from the SEC's website () and on our website () under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.
Contact:
Joel A. Fernandes
Threshold Pharmaceuticals, Inc.
650.474.8273
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.03.2012 - 14:05 Uhr
Sprache: Deutsch
News-ID 1097624
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SOUTH SAN FRANCISCO, CA
Phone:
Kategorie:
Trials
Anmerkungen:
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Threshold Pharmaceuticals Announces Multiple Data Presentations on TH-302 at the 2012 AACR Annual Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Threshold Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
